Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

We evaluated the benefits of adding 150 mg bicalutamide to standard care, that is radical prostatectomy, radiotherapy or watchful waiting (WW), in patients with localized or locally advanced prostate cancer.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J. Urol.

Title: The Journal of urology

ISSN: 0022-5347

ISSN (Print): 0022-5347

Publication date (Electronic): Nov 2004

Volume: 172

Issue: 5 Pt 1

Affiliations

[1 ] Department of Urology, University of Copenhagen, Rigshospitalet and Herlev Hospital, Copenhagen, Denmark. piv@rh.dk

Article

DOI: 10.1097/01.ju.0000139719.99825.54

PubMed ID: 15540741

SO-VID: 4f2e0c20-49a6-43f3-82d3-b884aaf606d4

History

Data availability:

Comments

Comment on this article

scite_

Smart Citations

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.